XML 17 R2.htm IDEA: XBRL DOCUMENT v3.24.4
CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2024
Sep. 30, 2023
Current assets:    
Cash and cash equivalents $ 6,431,095 $ 7,151,800
Accounts receivable, net of allowance for credit losses of $75,000 at September 30, 2024 and 2023 362,013 255,502
Inventories 438,592 330,027
Prepaid expenses and other current assets 815,970 389,241
Total current assets 8,047,670 8,126,570
Property and equipment, net 553,233 838,270
Other assets:    
Restricted cash 750,000 750,000
Intangible assets 2,698,975 2,698,975
Operating right of use asset 739,162 1,237,762
Total assets 12,789,040 13,651,577
Current liabilities:    
Accounts payable and accrued liabilities 1,793,427 2,270,388
Operating lease liability, current 545,912 498,598
Deferred revenue 58,785 76,435
Total current liabilities 2,398,124 2,845,421
Long term accrued liabilities 31,467 31,467
Deferred revenue, long term 194,000 194,000
Operating lease liability, long term 193,249 739,162
Deferred tax liability, net 684,115 684,115
Warrants classified as a liability 320,000 4,285,000
Total liabilities 3,820,955 8,779,165
Commitments and contingencies (Note G)
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2024 and 2023
Common stock, par value $0.001 per share; 200,000,000 shares authorized as of September 30, 2024 and 2023, 10,311,885 and 682,926 shares issued and outstanding as of September 30, 2024 and 2023, respectively 10,314 683
Additional paid in capital 318,805,058 307,397,623
Accumulated deficit (309,672,755) (302,447,147)
Applied DNA Sciences, Inc. stockholders' equity 9,142,617 4,951,159
Noncontrolling interest (174,532) (78,747)
Total equity 8,968,085 4,872,412
Total liabilities and equity 12,789,040 13,651,577
Series A Preferred stock    
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2024 and 2023
Series B Preferred stock    
Applied DNA Sciences, Inc. stockholders' equity:    
Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; -0- shares issued and outstanding as of September 30, 2024 and 2023